MELEXIS N.V.

MELE
Real-time Quote. Real-time  - 01/27 09:15:56 am
89.9EUR -2.76%

Melexis N.V. : Increase of volatility

Jordan Dufee
Senior Analyst

Strategy published on : 01/14/2021 | 02:52

long trade
Live

Entry price : 91.9€
Target : 105€
Stop-loss : 85€
Potential : 14.25%

A strong break-out to the upside has recently been seen in Melexis N.V.. The current technical chart pattern could allow for a continuation of the upward dynamic.
Investors have an opportunity to buy the stock and target the € 105.

Summary

● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

● The company has solid fundamentals for a short-term investment strategy.


Strengths

● Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.

● The company returns high margins, thereby supporting business profitability.

● The company is in a robust financial situation considering its net cash and margin position.

● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.

● Over the last twelve months, the sales forecast has been frequently revised upwards.

● Over the last seven days, analysts have been revising upwards their EPS estimates for the company.

● For the past twelve months, EPS forecast has been revised upwards.

● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

● The stock is in a well-established, long-term rising trend above the technical support level at 65.3 EUR


Weaknesses

● The stock is close to a major daily resistance at EUR 93.55, which should be gotten rid of so as to gain new appreciation potential.

● With an enterprise value anticipated at 7.27 times the sales for the current fiscal year, the company turns out to be overvalued.

● With an expected P/E ratio at 54.1 and 38.13 respectively for both the current and next fiscal years, the company operates with high earnings multiples.

● The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

© MarketScreener.com 2021
Copier lien
All news about MELEXIS N.V.
12/01
11/05
10/28
10/28
10/20